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Summary
Pulmonary arterial hypertension (PAH) is a vascular dis-
ease of unknown aetiology, characterised by an abnormal
thickening of the arterial wall that is responsible for an
increase in pulmonary vascular resistance. The haemody-
namic consequence of PAH is an increased afterload for
the right ventricle and, eventually, right heart failure. When
untreated, PAH has a grim prognosis with a median sur-
vival of about 2 to 4 years from diagnosis. In the last 10
years new orally administered compounds have demon-
strated clinical efficacy in controlled trials using various
surrogate endpoints to survival. Although the disease re-
mains without cure until now, the available phase III trials
have allowed evidence-based recommendations for the
medical management of these patients to be established.
It appears, however, that none of the compounds from the
three main therapeutic classes, endothelin receptor antag-
onists, agents acting on the nitric oxide–cyclic guanosine
monophosphate pathway (including phosphodiesterase
type 5 inhibitors and guanylate cyclase stimulator), and
prostanoid receptor agonists are able alone to control dis-
ease progression in every patient. Therefore combination
therapy with two or three drugs may be necessary in a sig-
nificant number of patients in order to maintain patients in,
or bring them to, a low risk profile. Several recent stud-
ies have now validated this approach for specific double or
triple drug regimens. It remains, however, unclear whether
an upfront combination is preferable to a sequential step-
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up approach based on clinical response. In addition, some
specific combination therapies have failed to demonstrate
superiority to single drug alone in randomised controlled
trials. Besides PAH-specific treatment, the place of nonspe-
cific pharmaceutical and nonpharmaceutical treatment has
been also recently clarified.
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Introduction
Since the last review on the therapy for pulmonary arterial
hypertension (PAH) in this Journal [1], several new sub-
stances have been studied in randomised controlled trials
(RCTs), and guidelines on the overall management of the
disease have been extensively updated [2, 3]. In this review
we will focus exclusively on the treatment of pulmonary
arterial hypertension group 1 according to the Nice 2013
classification [4], and restrict the analysis to adult patients.
Comprehensive guidelines addressing specifically the pae-
diatric population have been published recently [5]. Results
from RCTs performed in patients with PAH category 1 can-
not be extrapolated to other types of pulmonary hyperten-
sion, which have been much less thoroughly studied.
Nonspecific therapy
Nonspecific supportive therapies in PAH, including anti-
coagulation, oxygen, diuretics and digoxin are addressed
by expert opinion, owing to the lack of RCTs for most of
these drugs and despite the recent advances in PAH-specif-
ic drugs.
Anticoagulation
PAH is characterised by a prothrombotic state and its
pathophysiology includes in-situ thrombosis of small pul-
monary arteries [6]. PAH patients often have nonspecific
increased risk factors for venous thromboembolism includ-
ing heart failure, long-term intravenous catheters and im-
mobility. This, together with few old observational studies
showing favourable effects of oral anticoagulation (OAC)
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explains why OAC became widely used in group 1 PAH
[7].
However, the extent to which thrombosis plays a role in the
progression of PAH is unknown and data assessing the sur-
vival effect of OAC are mostly limited to retrospective and
single-centre studies. OAC needs to be balanced against the
risk of bleeding, the major concern being gastrointestinal
haemorrhage, which affects particularly patients with con-
nective tissue disease PAH (CTD-PAH) with endoluminal
telangiectasia and patients with porto-pulmonary hyperten-
sion.
In PAH the indication for OAC is still debated. In CTD-
PAH, the two recent analyses of the European and Amer-
ican pulmonary hypertension registries, which were not
designed to evaluate the effect of OAC on survival, con-
cluded that OAC may not be beneficial [8, 9]. For idiopath-
ic PAH these two studies show conflicting data with a sur-
vival benefit in the European COMPERA registry and no
survival advantage in the USA REVEAL registry. In both
analyses, only some of the patients were anticoagulated for
the entire observation period, 55% in the COMPERA study
and 25% in the REVEAL study. The difference in the tar-
get prothrombin time international normalised ratio (INR)
range (2–3 in COMPERA, 1.5–2.5 in REVEAL) may also
have played a role in the diverging results.
The latest European Society of Cardiology (ESC) /
European Respiratory Society (ERS) guidelines consider
OAC as a class IIb recommendation with a level C of evid-
ence for PAH groups 1.1 to 1.3 [3]. The use of OAC should
then be individualised. OAC may be considered in selected
PAH patients with increased risk factors for venous throm-
bosis. Concomitant conditions with a need for OAC such
as atrial fibrillation should be the main reason to treat these
patients.
Digitalis and diuretics
Diuretics are beneficial in the case of volume overload.
Loop diuretics are the first-line therapy. In patients with
clinical right heart failure with oedema of the gastrointest-
inal tract mucosa, intravenous administration may be more
efficient. Similarities in the effects of left and right
ventricular failure on the renin-angiotensin system suggest
that for patients in functional class 3 and 4, the addition of
aldosterone antagonists may be beneficial [10].
The long-term effect of digitalis in PAH is unknown, ex-
cept for patients with atrial arrhythmia in whom digoxin
slows the ventricular rate. Its use is controversial because
of its potential toxicity, which is increased in the event of
renal failure, and drug interactions.
Oxygen therapy
The use of oxygen therapy has been extrapolated from data
in patients with chronic obstructive pulmonary disease. In
hypoxaemic PAH patients, oxygen administration reduces
pulmonary venous resistance and is already recommended
when PaO2 is consistently <60 mm Hg [3]. However this
indication is controversial in congenital heart disease-asso-
ciated PAH as a randomised controlled study in 23 adult
patients showed no improvement in 6-minute walking dis-
tance, quality of life and survival with nocturnal oxygen
administration [11]. However, the only RCT of oxygen
therapy in PAH and inoperable chronic thromboembolic
pulmonary hypertension (CTEPH) has shown that patients
benefit from nocturnal oxygen therapy when they have a
mean nocturnal oxygen saturation <90%, even with pre-
served daytime oxygenation [12].
Altitude exposure may worsen pre-existing hypoxaemia
and current air travel recommendations propose in-flight
oxygen administration for patients with New York Heart
Association (NYHA) functional class III and IV [3].
However an uncontrolled study in 36 PAH patients sugges-
ted that functional class does not predict hypoxaemia dur-
ing a hypoxic challenge testing and that its assessment does
not identify who may have symptoms during aircraft travel
[13]. Oxygen therapy should also be considered in patients
living at altitude equal or superior to 1500 to 2000 m above
sea level.
Nonpharmacological treatment:
rehabilitation
Despite optimal medical treatment, most patients remain
symptomatic with exercise intolerance and fatigue [14, 15].
During exercise, mean pulmonary arterial pressure in-
creases dramatically while cardiac output does not rise as
much as expected. PAH patients may present decondition-
ing and have impaired peripheral oxygen utilisation, which
explains decreased peak oxygen consumption and early on-
set of anaerobic threshold.
A recent meta-analysis including 16 studies, among them 4
that were randomised, demonstrated that rehabilitation im-
proves exercise capacity (6-minute walk distance and peak
oxygen consumption [VO2]) and quality of life with only
few minor adverse events [16]. Among the 434 studied pa-
tients, all but 19 were in NYHA functional class II and III,
well-compensated under stable medication. More than 70%
of the patients had PAH, the others had CTEPH. Exercise
training protocols were all supervised; the majority were
low workload (10–60 W) and aerobic with some form of
resistance and respiratory training.
Since then a fifth randomised study including 86 stable pa-
tients with PAH (53%) and inoperable CTEPH (47%) in
NYHA functional class II and III has showed a significant
increase in peak VO2 and 6-minute walking distance along
with haemodynamic improvement [17].
In the ERS/ESC guidelines, rehabilitation was downgraded
from a class I to IIa recommendation with a B level of
evidence because of absence of agreement regarding the
methods of exercise, the intensity and duration of training
and the characteristics of the supervision. In view of the
latest publications, we believe that rehabilitation should be
offered to group 1 and inoperable CTEPH stable patients
in NYHA functional class II or III as add-on to optimal
medical therapy. Highly supervised low-workload aerobic
training should, however, be offered in centres with well-
established experience in training pulmonary hypertension
patients and in close collaboration with a pulmonary hy-
pertension centre in order to avoid potentially deleterious
side effects. Exercise should be discontinued in the case of
light-headedness, chest pain, palpitations or syncope [18].
High-intensity exercise and Valsalva manoeuvres are not
recommended. The usefulness of oxygen supply in patients
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desaturating during exercise and of increased physiother-
apy in CTD-PAH has still to be demonstrated. As in other
diseases, the challenge is to make severely affected patients
change their life-style and continue regular exercise after
the training programme.
Specific medical therapy for PAH
The current hypothesis addressing PAH pathogenesis is a
model of acquired hits occurring on a favourable genetic
background [19]. At some point, imbalance of the three
major pathways of the endothelial function, namely the
prostacyclin (PGI2), the endothelin (ET-1) and the nitric
oxide (NO) pathways, has been consistently shown to be
involved in the disease process, leading to a triad of con-
striction, remodelling and thrombosis of small pulmonary
arteries [6, 20]. Presently, all drugs approved for the treat-
ment of PAH in Switzerland target one of these three path-
ways, besides calcium channel blockers for reactive PAH
(fig. 1). Only these drugs will be commented on in this re-
view, including also selexipag, which will enter the review
process for approval by regulatory authorities in Switzer-
land in 2016, and which has already been integrated in the
2015 guidelines [3].
ET-1 is the most potent vasoconstrictor synthesised in the
human body and induces smooth muscle cell proliferation
through the binding of endothelin receptors A and B (ETA/
ETB) [21, 22]. In PAH, ET-1 biosynthesis is up-regulated,
as demonstrated by both higher serum levels and increased
ET-1 staining in the pulmonary arteries of lung specimens
taken after transplantation [23]. On the side of vasodilators,
Figure 1
Established pathological pathways modulated by pharmacological
substances currently used or in investigation for the treatment of
pulmonary arterial hypertension. Antagonists or inhibitors are in
red, activators or analogues are in green. (Reproduced with
permission from: Humbert M, Lau EMT, Montani D, Jais X, Sitbon
O, Simonneau G. Advances in therapeutic interventions for patients
with pulmonary arterial hypertension. Circulation.
2014;130:2189–208.)
cAMP = cyclic adenosine monophosphate; cGMP = cyclic
guanosine monophosphate; GTP = guanosine triphosphate; ET =
endothelin; ETA = endothelin type A receptor; IP = prostaglandin I2;
NO = nitric oxide; PDE-5 = phosphodiesterase type 5; sGC =
soluble guanylate cyclase
NO bioavailability is reduced by numerous mechanisms in
PAH, and soluble guanylate cyclase (sGC), which gener-
ates cyclic guanosine monophosphate (cGMP) in smooth
muscles cells in response to NO, is partially inactivated be-
cause of high levels of oxidative stress [24]. Furthermore,
phosphodiesterase type 5 (PDE-5) has been found to be up-
regulated in lung homogenates of patients with PAH, lead-
ing to quicker inactivation of cGMP [25]. Finally, PGI2 ex-
pression is also severely reduced in PAH [26], and to a
lesser level its specific IP receptor in the smooth muscle
cells of pulmonary arteries [27].
Calcium channel blockers
The invasive haemodynamic assessment of PAH group 1.1
to 1.3 should always involve vasoreactivity testing [3] with
inhaled NO as the standard of care or with alternative
agents such as iloprost. In the case of substantial improve-
ment under testing, calcium-channel blocker monotherapy
is warranted. It must, however, be stated that about 50% of
the initial responders may lose this characteristic and face
worsening PAH after 1 year, with the need to initiate anoth-
er PAH-specific therapy [28].
The prostacyclin pathway
Epoprostenol was historically the first treatment to have
shown efficacy in nonreactive PAH and the only one to
have brought a survival benefit in a RCT, with 100% sur-
vival at 12 weeks in the epoprostenol group as compared
with 80% in the conventional treatment group (p = 0.003)
[29]. This drug is a freeze-dried preparation of PGI2 restric-
ted to continuous intravenous use through a central venous
catheter and a dedicated pump. In spite of the dramatic im-
provement in haemodynamics, functional capacity and sur-
vival, the widespread use of epoprostenol is limited by the
occurrence of a rather high rate of catheter-related infec-
tions and by the risk of a possibly fatal rebound pulmon-
ary hypertensive crisis in the case of drug interruption due
to catheter thrombosis or pump malfunction [30]. This lat-
ter risk is related to the particularly short half-life (≈6 min)
of epoprostenol. Consequently, epoprostenol must be initi-
ated only in expert centres, even with the improved con-
venience of a new thermostable formulation avoiding twice
daily line manipulation [31].
In order to increase the safety of prostanoid therapy, prosta-
cyclin analogues with longer half-lives such as tresprostinil
and iloprost were developed and tested through alternative
routes of administration. Subcutaneous tresprostinil is rap-
idly absorbed with complete bioavailability and it offers
similar pulmonary vascular resistance reduction to intra-
venous epoprostenol or tresprostinil itself at maximum tol-
erated doses [32], as well as a dose-dependent increase in
exercise capacity [33]. In practice, treprostinil, like the oth-
er prostanoids, is initiated at low dose and progressively
up-titrated until typical side effects like jaw pain, flushing,
hypotension or diarrhoea occur. The optimal infusion rate
is considered as the maximum tolerated dose. Besides gen-
eral prostanoid side effects, the continuous drug infusion
under the skin also invariably produces local pain and cu-
taneous inflammation, and possible injection site infection,
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with high discontinuation rates over the mid- and long-
term, which again limit wide implementation of
prostanoids in clinical practice [34]. Intravenous infusion is
also possible with tresprostinil, but there is so far no reli-
able multicentre randomised controlled trial to validate this
option. Finally, iloprost is the third approved prostanoid for
parenteral use in Switzerland. It can be used via inhalation
with specific dedicated nebulisers, but plays a limited role
in PAH therapy as a result of the six to nine daily adminis-
trations and possible mitigated long-term efficacy [35, 36].
The orally available nonprostanoid agonist at the IP recept-
or, selexipag, has been evaluated in the multicentre ran-
domised placebo-controlled GRIPHON trial, whose res-
ults were published recently [37]. Selexipag is a prodrug
that is rapidly transformed to an active metabolite with an
8-hour half-life, enabling administration twice daily. This
active metabolite displays high specificity for the IP recept-
or, with positive vasodilator and antiproliferative effects
on the smooth muscle cells of pulmonary arteries, but also
with typical side effects related to IP receptor activation
in the stomach and gut (nausea, diarrhoea), as well as in
systemic vessels (hypotension, headache). Selexipag needs
progressive up-titration and the optimal dose is considered
to be the maximum tolerated dose. Under these conditions,
the GRIPHON trial showed a significant 40% reduction of
a combined morbidity-mortality endpoint in the active drug
arm, with benefit both in naïve patients and in those already
on background therapy [37]. The study was limited to pa-
tients in functional class II or III.
The endothelin pathway
Selective blocking of the endothelin receptor A (ETA) can
be obtained with ambrisentan and dual blocking of the
endothelin receptors A and B (ETA/B) with bosentan or
macitentan, which are all oral drugs. Ambrisentan and
bosentan were licensed on the basis of 12–16 weeks ran-
domised placebo-controlled trials demonstrating improve-
ments in exercise capacity as measured by the 6-minute
walking distance (6MWD) (placebo-controlled increase by
31–76 m) [38–47]. Although the 6MWD can be considered
as a predictor of clinical stability and mortality in PAH
[48], its relevance to long-term clinical outcome is ques-
tionable. In a recent meta-analysis of 3112 patients from 22
clinical trials, 6MWD changes measured under treatment
were not predictive of clinical outcome events like all-
cause mortality, hospitalisation for PAH, lung transplanta-
tion and initiation of parenteral therapy [49]. Furthermore,
improvement in 6MWD may not be apparent in less severe
patients with normal or near-normal baseline walking dis-
tance because of a ceiling effect [50]. Nevertheless, long-
term open label studies at 24 to 51 months confirmed the
benefit of both ambrisentan and bosentan [39, 44], includ-
ing for NYHA stage II (mildly symptomatic) patients [46].
Increased incidence of peripheral oedema, elevation of liv-
er aminotransferases, mild anaemia and headaches are the
major side effects of endothelin receptor antagonists
(ERAs). With bosentan, the annual rate of aminotransferase
elevation above 3 times the upper limit of normal is 10.1%,
and discontinuation of therapy was required in 3.2% of
patients in a 30-month post-marketing study on 4994 pa-
tients [51]. Aminotransferase elevation is dose-dependent,
which warrants starting with low doses, and fully reversible
after drug dose reduction or discontinuation. In spite of
this hepatoxicity, first-line bosentan therapy can be safely
administered in porto-pulmonary hypertension with Child-
Pugh A and B cirrhosis, but less is known about Child-
Pugh C cirrhosis [52]. Bosentan is cleared by CYP3A4 and
CYP2C9 and is also an inducer of these two enzymes. Ser-
um concentrations of concomitant drugs metabolised by
CYP3A4 and CYP2C9 may thus be decreased, but most
importantly, administration of strong inhibitors of these en-
zymes would enhance bosentan toxicity. With ambrisentan,
the risk of liver injury is lower [38]; therefore it can safely
replace bosentan in cases of liver toxicity [53]. Drug-drug
interactions are also of less importance with ambrisentan,
which is mainly cleared by glucuronide conjugation, but
peripheral oedema is more common.
Macitentan is the last member of the ERA family deve-
loped for PAH and, through a modification of its chemical
structure, is able to achieve enhanced tissue penetration,
long-lasting pharmacologically active metabolites, an in-
creased receptor affinity and more sustained receptor bind-
ing [54]. These properties allow a once-a-day regimen with
lower doses and optimised safety profile, and with no effect
on liver enzymes in phase II trials [55], but as ERAs may
still induce hepatotoxicity after months or years, longer tri-
als are needed to demonstrate truly the lack of delayed
liver-related side effects [56].
With the phase III SERAPHIN trial, macitentan is the first
PAH-specific therapy to have been studied in a long-term
event-driven trial, which is a true paradigm shift as com-
pared with the earlier short-term trials based on the surrog-
ate 6MWD endpoint [57]. The SERAPHIN primary end-
point was designed to reflect the true progression of PAH
and was defined as the time to a composite of mortality,
atrial septostomy, lung transplantation, initiation of
prostanoid therapy or PAH worsening. PAH worsening was
further defined as the simultaneous occurrence of three cri-
teria, namely persistent (>15%) 6MWD decrease, worsen-
ing PAH symptoms (increase in functional class or symp-
toms of right heart failure) and need for additional PAH
therapy including intravenous diuretics. Actually, after a
mean follow-up of about 2 years, macitentan reduced this
morbidity–mortality endpoint by 45% (relative risk) and
by 12.9% (absolute risk) (p <0.001) in the 10-mg group.
The effect was positive in both naïve patients and patients
on background therapy (mostly PDE-5 inhibitors). Of note,
all-cause mortality occurring as the first clinical event was
not significantly different with macitentan as compared
to placebo (hazard ratio 0.64; 97.5% confidence interval
0.29–1.42) and it must also be emphasised that there were
almost no patients in functional class IV in this study. Fur-
thermore, although the robustness of the SERAPHIN tri-
al may drive physicians to choose macitentan in naïve pa-
tients, there are currently no direct comparison studies to
support the switch from an “old” ERA to the new com-
pound, especially in stable patients. Regarding safety, ma-
citentan was overall well tolerated, but anaemia occurred
in 13.2% of treated patients, with haemoglobin level falling
<8 g/l in 4.3% of subjects [57].
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The NO-cGMP Pathway
As in corpus cavernosum, the type 5 isoform is the most
abundant phophodiesterase in pulmonary arteries, and two
orally active PDE-5 inhibitors licensed for erectile dysfunc-
tion are also approved for PAH treatment. Both sildenafil
and tadalafil induce pulmonary vasodilatation in PAH (max-
imal effect after 60 and 75–90 minutes, respectively [58].
Sildenafil has also been shown to inhibit the proliferation
and to stimulate the apoptosis of pulmonary artery smooth
muscle cells in vitro [59, 60]. As for the first ERA gener-
ation, sildenafil and tadalafil were licensed on the basis of
12–16-week randomised placebo-controlled trials [61–63]
demonstrating efficacy by improving 6MWD. Because the
SUPER-1 study showed no statistical difference in 6MWD
between 20, 40 or 80 mg sildenafil, USA and European reg-
ulatory authorities approved the drug at 20 mg three times
daily (t.i.d), but because pulmonary vascular resistance de-
creases linearly with increasing sildenafil dose, many phys-
icians up-titrate their patients up to 80 mg t.i.d. if necessary
[64]. Also, the open-label extension of the SUPER-1 study
(SUPER-2) suggested long-term efficacy of sildenafil given
at 80 mg t.i.d but uncertainty remains with the 20 mg dose
[62]. As compared with sildenafil, tadalafil has a longer
plasma half-life (17.5 hours as compared with 4 hours) and
can be given once a day. It also increases 6MWD in a
dose-dependent manner with maximal effect at 40 mg (table
1) [63]. In patients receiving tadalafil 20 or 40 mg, the
improvements in 6MWD demonstrated in the 16-week
PHIRST study appeared sustained for up to 52 additional
weeks of treatment in PHIRST-2 [65]. Both drugs are gen-
erally well tolerated and most side effects are essentially
related to vasodilatation, such as headache, flushing, epi-
staxis, dyspepsia, diarrhoea, myalgia and hypotension. In
some cases such as PAH associated with human immunode-
ficiency virus infection, the PDE-5 ihibitor dose may have
to be reduced, because of interaction with antiretroviral ther-
apy. Ocular complications with blurred vision and altered
colour perception due to an effect of sildenafil on retinal
PDE type 6 were described, but doses up to 80 mg t.i.d have
recently been shown to be safe from an ocular perspective
[66].
Active on the NO-cGMP pathway, riociguat is the most re-
cently approved drug for PAH and the only one approved in
Switzerland for inoperable CTEPH. Conceptually, it repres-
ents a novel class of drugs that sensitizes sGC to low NO
levels and further activates oxidised sGC independently of
NO [67]. The ability to produce cGMP even in the absence
of NO might confer on riociguat a potential advantage over
PDE-5 ihibitors, whose effect may be hampered by the re-
duced NO availability in PAH. At a 1.0–2.5 mg dose given
t.i.d. and titrated according to blood pressure, riociguat de-
creased pulmonary arterial pressure while cardiac index in-
creased in a phase II study involving 33 PAH patients [68].
The phase III PATENT-1 trial kept to the traditional 12-week
6MWD primary endpoint, and time to clinical worsening
was only one of the secondary endpoints [69]. This study
included almost only class II and III patients and showed a
placebo-controlled 6MWD increase by 36 m, a significant
delay in clinical worsening (p = 0.005) as well as a favour-
able safety profile. The most common serious adverse event
was syncope and hypotension which occurred in 10% of pa-
tients in the 2.5-mg maximum group. The 6MWD improve-
ment persisted at 1 year (+51 m) as compared with baseline,
and functional class improved in 33%, stabilised in 66%
and worsened in 6% [70]. Of note, combining riociguat with
sildenafil in order to look for a synergistic effect was re-
cently shown to bring excessive systemic hypotension with
no favourable effect on haemodynamics or exercise capa-
city, and is therefore not recommended [71].
Treatment strategies for PAH
Monotherapy
Monotherapy refers to treating PAH with a single drug.
This strategy relies on a solid background of numerous
studies showing clinical benefit with any of the drugs de-
scribed above when tested versus placebo in naïve patients.
Table 1 shows the published evidence for monotherapy (tri-
al data concerning patients on background therapy have
been omitted on purpose) with all drugs approved in
Switzerland, with numbers of patients, study duration and
results for the primary endpoint. What may first appear on
looking over the table is that the sub-analysis restricted to
naïve patients recruited in the SERAPHIN trial currently
offers the only evidence that oral monotherapy may delay
disease progression in PAH [57]. However, while other
randomised-controlled trials also validate some short-term
benefit on soft endpoints, long-term follow-up studies con-
sistently show a significant number of patients initially on
monotherapy who are either dead (15–60%), or on com-
bination therapy (7–31%). This most probably reflects
worsening PAH or a clinical failure (31–37%) after 1.5 to
4 years. These considerations, added to results from meta-
analyses concluding that monotherapy alone is unsatisfact-
ory regarding hard clinical outcomes [76, 77], indicates
that oral monotherapy is not enough for the long term,
at least in a subset of patients with more severe disease.
Regarding parenteral therapy, only epoprostenol showed
increased survival in monotherapy class III and IV patients,
and the effects of none of the other parenteral prostanoids
were assessed on hard clinical endpoints.
Currently, initial monotherapy is a recommended option for
the management of PAH patients at low or intermediate
risk. Patients on monotherapy should then be carefully and
regularly reassessed for disease progression, and combina-
tion therapy should be applied for all deteriorating subjects
and for all subjects who persist with an unsatisfactory re-
sponse to treatment (see below) [3].
Combination therapy
Randomised trials as well as clinical practice have shown
that a single drug regimen is frequently not sufficient to
control the patient’s symptoms and to decrease the risk
of clinical deterioration. Pulmonary hypertension experts
have empirically used combinations of drugs for the most
severely ill, despite initial lack of published evidence [78].
Since then, several RCTs have attempted to address the is-
sue, albeit with different designs, endpoints and durations,
making comparisons hazardous. These studies are summar-
ised in table 2. When considering the drugs presently avail-
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able (including selexipag) and excluding combinations
within the same class of medication, about 30 possible
double drug regimens are available. It is important to note
that not all combinations have been tested in RCTs and,
among those evaluated, not all proved to be positive. In
particular, double-drug regimens including the ERA
bosentan were negative in four trials including the recently
published COMPASS-2 trial [79]. Whether these failures
were due to inadequate study design, insufficient statistical
power or the consequence of a specific drug interaction,
leading to decreased blood levels of either substance, is not
known. However the two most recent substances riociguat
and selexipag in association with bosentan demonstrated
positive results [37, 69].
Based on these data, the ESC/ERS guidelines let the phys-
ician the choice to prescribe either a monotherapy or a
double therapy to a patient newly diagnosed with PAH, in
functional NYHA class II–III [3]. In contrast, a patient dia-
gnosed at NYHA stage IV should be treated with an ini-
tial combination that includes an intravenous prostanoid. It
Table 1: Trials investigating monotherapy in PAH. Only numbers (N) from naïve patients are reported while data from patients on background therapy have been omitted.
Trials that did not describe separately naïve patients are not shown.
Short Term Study 251;
2001 [41]
N = 32; 12
wks
Placebo-
contr.
6’WD (+76
m)
BREATHE-1;
2002 [42]
N = 213; 16
wks
Placebo-
contr.
6’WD (+44
m)
EARLY;
2008 [74]
N = 185
(classII) 24
wks
Placebo-
contr.
PVR
(–22.6%)
ARIES-1;
2008 [40]
N = 202; 12
wks
Placebo-
contr.
6’WD
(+31 m/5
mg)
(+51 m/10
mg)
"ARIES-2;
2008 [40]
N = 192; 12
wks
Placebo-
contr.
6’WD (+59
m/5 mg)
SUPER-1
2005[61]
N = 278; 12
wks
Placebo-
contr.
6’WD
(+45 m/20
mg)
(+46 m/40
mg)
(+50 m/80
mg)
SINGH
2006[72]
N = 20; 6
wks
Placebo-
contr.
6’WD (+65
m)
PHIRST
2009[63]
N = 144; 16
wks
Placebo-
contr.
6’WD (+44
m)
PATENT-1
2013[73]
N = 89; 12
wks
Rioc 2.5max
Vs placebo
6’WD (+38
m)
BARST
1996[29]
N = 81
(class III–IV)
12 wks
Placebo-
contr.
6’WD (+113
m)
Survival
(100% vs
80%)
Simonneau
2002 [33]
N = 470; 12
wks
Placebo-
contr.
6’WD
(+16
m/overall)
(+36
m/>13.8 ng/
kg)
AIR
2002[35]
N = 203
(class III–IV)
12 wks
Placebo-
contr.
6’WD (+59
ml)
FC improved
(+17.2%)
Long Term McLaughlin
2005 [44]
N = 169; 24
mths
Open label
observat.
70% alive
monoRx
7% alive
combiRx
12% alive
otherRx
EARLY long
-t 2014 [46]
N = 144
(classII) 4
yrs
Open label
observat
52% alive
monoRx
31% alive
combiRx
15%
mortality
Oudiz 2009
[39]
N = 383; 2
yrs
Open label
obs.
56% alive
monoRx
12% alive
combiRx
15%
mortality
AMBITION
2015 [75]
[75] N = 126;
~484 days
Ambri-contr.
arm
observational
37% clin
failure
SERAPHIN;
2013 [57]
N = 184; 36
mths
Maci 10 mg
vs plac.
Clinical
worsenirg
HR = 0.45
(95%CI
0.28–0.72)
SUPER-2
2011[62]
N = 259; 3
years
Open label
obs
58% alive
monoRx
12% alive
combiRx
23%
mortality
AMBITION
2015 [75]
N = 121;
~484 days
tada-contr.
arm
observational
31% clin
failure
McLaughlin
2002 [30]
N = 162; 36
mths
Open label
observ.
62.5%
survival
Barst 2006
[34]
N = 860; 4.5
yrs
Open label
observ.
23%
stopped
(AE)
14%
stopped
(disease
progr.)
15% alive on
combiRx
26% alive on
monoRx
16%
mortality
Opitz 2005
[36]
N = 76; 5 yrs
Open label
observ.
87% events
(death, lung
Tx, switch to
IV,
combination
therapy)
Survival
40%
Bosentan Ambrisentan Macitentan Sildenafil Tadalafil Riociguat Epoprostenol Treprostinil Iloprost
Grey: observational data; Orange: short-term randomised controlled trial with soft endpoints (PVR or 6’WD or functional class); Green: short/long-term randomised
controlled trial with hard endpoints.
6’WD = 6-minute walking distance; AE = adverse event; Ambri = ambrisentan; clin = clinical; contr = controlled; combiRx = combination therapy; FC = functional class;
Maci = macitentan; monoRx = monotherapy; mths = months; observ = observational; Plac = placebo; progr = progression; Rioc = riociguat; tada = tadalafil; Tx =
transplantation; wks = weeks; yrs = year
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is not known at the present time if selexipag might replace
intravenous prostanoids in this setting and this point will
have to be addressed by specific RCTs that include patients
in NYHA class IV. Although NYHA functional class is a
major determinant of prognosis in PAH, other independ-
ent risk factors have been validated, including the subtype
of PAH, systemic blood pressure, the diffusing capacity of
the lung for carbon monoxide and pulmonary vascular res-
istance [3] (table 3). In particular, scleroderma-associated
PAH has been shown to have a worse prognosis [80].
These risk factors have been extensively studied in the
USA-based REVEAL registry [81] and may provide addi-
tional help to the clinician for the choice of treatment in pa-
tients with NYHA class II or III. The benefit of such a risk
stratified treatment has, however, not been validated pro-
spectively and is therefore not yet included in the most re-
cent guidelines.
Concerning initial (upfront) double combination therapy,
the association ambrisentan + tadalafil, which has been
specifically analysed in the AMBITION study [75], re-
ceives grade I, level B in the European guidelines, whereas
other combinations with ERAs and PDE-5 inhibitors are
graded II, level C [3]. Moreover, in scleroderma-associated
PAH, this combination has shown significant efficacy in an
open long-term trial [82].
Sequential versus simultaneous (upfront) combined
therapy
The AMBITION study demonstrated that upfront combin-
ation of ambrisentan with tadalafil was superior to either
drug alone [75]. Therefore the initiation of monotherapy
with one of these two medications should be restricted to
patients with a low risk profile. However, the AMBITION
study has not demonstrated that upfront therapy was super-
ior to a sequential design, where the second drug is intro-
duced when the target of PAH treatment has not been met
after an observational period of 3 to 6 months. One might
fear that with this step-wise approach the clinical worsen-
ing of a patient receiving a single drug would be eventu-
ally impossible to recover. However the PATENT-2 study,
the open-label extension of the RCT for riociguat, demon-
strated that patients initially on placebo during the blinded
phase recovered to a similar extent to the active group dur-
ing the extended phase, without increased mortality [71].
Another inconvenience of upfront double therapy is the oc-
currence of adverse events without knowing which one of
the two medications is the culprit. Finally, an upfront treat-
ment does not allow identification of patients who are en-
tirely nonresponsive to a class of substance.
Apart from patients in NYHA IV, it appears therefore wise
to adopt a sequential regimen, while taking care to shorten
the delay when the initial risk assessment is elevated (e.g.,
REVEAL score ≥10).
An upfront triple drug strategy has not been tested in RCTs,
but an observational study has been recently reported by
the French group in 19 severe PAH patients. These results
demonstrated an excellent clinical response under this ag-
gressive approach [83]. Such a design should be restricted,
however, to highly selected class IV patients.
Monitoring the therapy
Follow-up of patients has been recently emphasised and
structured into treatment goals [3] based on validated
markers of morbidity and mortality in distinct cohorts [81,
84, 85] (table 3). It is assumed that the correction of these
risk factors under therapy will have a positive impact on
survival. We should, however, remain cautious as these
Table 2: Published clinical studies in which double therapy was compared with single therapy plus placebo. In the second to lowest row are the drugs tested against
placebo, and in the left-hand column is shown the patients’ existing regimen. In the BREATHE-2 and the AMBITION studies, both drugs were introduced simultaneously.
Ambrisentan AMBITION+
TCW n = 253
positive
Patent-1
6WD n = (194)1
positive
Griphon
TCW n = (94)1
positive
Triumph3
6MWD n = 82
positive
Bosentan – NCT297+
6MWD n = 103
negative
Phirst
6MWD n = 42
negative
Patent-1
6WD n = (194)1
positive
Freedom-C3
6MWD n = 32
negative
Griphon
TCW n = (94)1
positive
Macitentan
Triumph
6MWD n = 35
positive
Sildenafil Compass-2
TCW n = 167
negative
Seraphin
TCW n = (150)1
positive
Freedom-C
6MWD n = 26
negative
Griphon
TCW n = (189)1
positive
Tadalafil AMBITION+
TCW n = 253
positive
Seraphin
TCW n = (150)1
positive
Griphon
TCW n = (189)1
positive
Riociguat
Prostanoid Breathe-2+
PVR n = 33
negative
Seraphin
TCW n = 152
Paces
6MWD n = 267
positive
Patent-1
6MWD n = 282
Drug Ambrisentan Bosentan Macitentan Sildenafil Tadalafil Riociguat Prostanoid Selexipag
Class Endothelin receptor antagonist Phosphodiesterase V inhibitor cGMP activ. Prostacyclin receptor pathway
Green = positive studies. Red = negative studies.
6MWD = 6-minute walking distance; PVR = pulmonary vascular resistance; TCW = time to clinical worsening.
1 indicates that detailed numbers for each drug are not available. The figure in parentheses is for the whole class. 2 The number of patients is too low to prove efficacy.
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risk factors are surrogate markers for mortality and, conse-
quently, the correction of one of them does not guarantee
automatically that survival will be better, as several unfor-
tunate examples in the medical literature have previously
shown (e.g., arrhythmia in left heart failure). However, tak-
ing into account not one but several surrogate markers to-
gether, including clinical signs, imaging studies and labor-
atory tests, makes the assumption more robust even if this
strategy has not been validated in a prospective randomised
trial. In clinical practice it is recommended that if several
modifiable risk factors persist or appear under treatment,
the medication be increased from a one- to two-drug regi-
men or from double to triple drug therapy [3]. When the
goals are not met under a triple drug regimen, including in-
travenous prostanoids, lung transplantation should be con-
sidered and the patients referred to a lung transplant centre,
if they qualify for such a treatment. Contrary to a common
belief, follow-up of systolic pulmonary pressure by means
of echocardiography is not valid for risk assessment.
Indeed, a decreasing systolic pulmonary arterial pressure
may indicate the onset of right ventricular failure.
Occasionally, the clinician may face the question of de-
creasing the number of PAH-specific drugs. Apart from
side effects problems, this may arise in some drug-induced
PAH [86], or HIV-associated PAH or portopulmonary PH
after successful liver transplantation, but is exceptional in
idiopathic PAH. Such a decision should be made only after
a thorough assessment including repeated right heart cath-
eterisation.
Conclusion
The number of substances available for the treatment of
PAH has increased during the last 8 years, but remains
within the three therapeutic targets identified in the early
2000s [87], and PAH remains a disease with poor prognos-
is. Combination therapy has been more and more valid-
ated through fairly large randomised trials with clinically
relevant endpoints and with registry data. Today, because
therapy is more and more complex and includes potentially
harmful drugs, global management in expert centres with
ambitious treatment goals and comprehensive functional,
biological and haemodynamic follow-up is the standard of
care.
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Figures (large format)
Figure 1
Established pathological pathways modulated by pharmacological substances currently used or in investigation for the treatment of pulmonary
arterial hypertension. Antagonists or inhibitors are in red, activators or analogues are in green. (Reproduced with permission from reference [20]
Humbert M et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189–208.)
cAMP = cyclic adenosine monophosphate; cGMP = cyclic guanosine monophosphate; GTP = guanosine triphosphate; ET = endothelin; ETA =
endothelin type A receptor; IP = prostaglandin I2; NO = nitric oxide; PDE-5 = phosphodiesterase type 5; sGC = soluble guanylate cyclase
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